Daniele Santini
Policlinico Umberto I · 1,348 works · 33,092 citations · h-index 86
Top works
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.
- Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- Bone health in cancer: ESMO Clinical Practice Guidelines
- Guillotine Needle Biopsy as a Supplement to Endosonography in the Diagnosis of Gastric Submucosal Tumors
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
- The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline
- Management of cancer pain: ESMO Clinical Practice Guidelines
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
- Zoledronic Acid-Related Angiogenesis Modifications and Survival in Advanced Breast Cancer Patients
- Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
- Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
- Fever After Zoledronic Acid Administration Is Due to Increase in TNF- α and IL-6